Abstracts tagged "registry"

Abstract Number: 0153 • ACR Convergence 2025
Patient Experience and Implementation of an Electronic Patient-Reported Outcome Measures (ePROM) System for Remote Monitoring in BIOBADASER
Isabel Castrejón Fernández¹, Lucia Otero², Antonio Mera-Valera³, Alicia Garcia⁴, Silvia Gomez-Sabater⁵, Raquel Martín-Domenech⁶, Jose Alvaro-Gracia⁷, Juan Camilo Sarmiento-Monroy⁸, Beatriz Ventosa² and Fernando Sánchez-Alonso⁹, ¹Department of Rheumatology. Hospital General Universitario Gregorio Marañon. IiSGM. Universidad Complutense Madrid, Madrid, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³H. Clínico Universitario de Santiago, Santiago de Compostela, ⁴Rheumatologist, La Laguna, Spain, ⁵Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ⁶H. Universitario de Elda, Elda, Spain, ⁷Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Department of Rheumatology, Hospital General Universitario Gregorio Marañón and Faculty of Medicine, Complutense University of Madrid, Madrid, Spain, ⁸Hospital Clínic Barcelona, Barcelona, Spain, ⁹Sociedad Española de Reumatología, Madrid, Spain
Background/Purpose: Patient-Reported Outcome Measures (PROMs) are integral to shared decision-making and quality improvement in rheumatology. They are recommended for monitoring treatment response, assessing quality of…
Abstract Number: 0655 • ACR Convergence 2025
Blood pressure remains elevated in patients initiating voclosporin with low baseline blood pressure: evidence from patients in routine clinical care
Eric Roberts¹, gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California, San Francisco, SF, CA, ²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³UCSF, San Francisco, CA
Background/Purpose: Hypertension was a common adverse event in RCTs testing voclosporin, an oral calcineurin inhibitor approved in 2021 to treat lupus nephritis (LN). In these…
Abstract Number: 1452 • ACR Convergence 2025
Clinical and Demographic Characteristics of Treatment-Refractory Axial Spondyloarthritis: Data from the Greek AxSpA Registry
Nikolaos Kougkas¹, Konstantinos Tsafis², Dimitrios Deligeorgakis³, Vasileios Papadopoulos⁴, Nikolaos Fytanidis⁵, Michail Krikelis⁶, Evangelia Mole⁷, Sousana Gazi⁷, Nikolaos Koletsos⁸, EVRIPIDIS KALTSONOUDIS⁹, Paraskevi V Voulgari¹⁰, Anastasios Karamanakos¹¹, Maria Pappa¹², Maria Tektonidou¹³, Petros Sfikakis¹⁴, Kalliopi Klavdianou¹⁵, aggelos Banos¹⁶, Eleni Kalavri¹⁷, Konstantinos Kottas¹⁸, Gkikas Katsifis¹⁸, MARIA KONSTA¹⁹, Eleftheria Grika²⁰, Charalampos Sfontouris²⁰, Evgenia Mavrea²¹, Christos Koutsianas²², Evangelia Kataxaki²³, Eleni Sampatakaki²⁴, Konstantina Zoupidou²⁵, Pelagia Katsimpri²⁶, Alexios Iliopoulos²⁷, Georgios Iliopoulos²⁸, Dimitrios Daousis²⁹, Ilias Bournazos³⁰, DIMITRIOS KAROKIS³¹, Dimos Patrikos³², Theodoros Dimitroulas³, Dimitrios Vassilopoulos²¹, George E Fragoulis³³ and Charalampos Papagoras³⁴, ¹⁴th Department of Internal Medicine, Aristotle University, Thessaloniki, Thessaloniki, Greece, ²Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, Fourth Department of Internal Medicine, Thessaloniki, Greece, Thessaloniki, Thessaloniki, Greece, ³Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, Fourth Department of Internal Medicine, Thessaloniki, Greece, Thessaloniki, Greece, ⁴Department of Medicine Democritus University of Thrace, Laboratory of Anatomy, Alexandroupolis, Greece, Alexandroupolis, Evros, Greece, ⁵University Hospital of Alexandroupolis, Democritus University of Thrace, First Department of Internal Medicine, Alexandroupolis, Greece, Alexandroupolis, Greece, ⁶KAT Hospital, Athens, Department of Rheumatology, Athens, Greece,, Athens, Attiki, Greece, ⁷Rheumatology department, KAT General Hospital of Attica, Athens, Attiki, Greece, ⁸School of Health Sciences, Faculty of Medicine, University of Ioannina, Department of Rheumatology, Ioannina, Greece, Ioannina, Ioannina, Greece, ⁹Rheumatology Clinic, University of Ioannina, IOANNINA, Ioannina, Greece, ¹⁰Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Ioannina, Greece, ¹¹Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Laiko”, First Department of Propedeutic and Internal Medicine, Athens, Greece, Athens, Greece, ¹²Rheumatology and Clinical Immunology Unit, ⁴th Department of Internal Medicine, Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ¹³National and Kapodistrian University of Athens, Athens, Greece, ¹⁴NKUA - SCHOOL OF MEDICINE, Athens, Greece, ¹⁵Asklepieion" General Hospital, Athens, Department of Rheumatology, Αthens, Greece, Kaisariani Athens, Greece, ¹⁶Asklepieion" General Hospital, Athens, Department of Rheumatology, Αthens, Greece, Athens, Attiki, Greece, ¹⁷"Asklepieion" General Hospital, Athens, Department of Rheumatology, Αthens, Greece, Athens, Greece, ¹⁸Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece, Athens, Greece, ¹⁹Sismanoglion Hospital, Athens, Greece, Marousi, Attiki, Greece, ²⁰Evaggelismos Athens General Hospital, Department of Rheumatology, Athens, Greece, Athens, Greece, ²¹Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Hippokration”, Clinical Immunology-Rheumatology Unit, ²nd Department of Medicine and Laboratory, Athens, Greece, Athens, Greece, ²²Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Hippokration”, Athens, Greece, ²³General Hospital Elefsinas Thriaseio,Attica, Rheumatology Department, Athens, Greece, Athens, Greece, ²⁴Joint Academic Rheumatology Program, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, ⁴th Department of Internal Medicine, Athens, Greece, Athens, Attiki, Greece, ²⁵Joint Academic Rheumatology Program, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, ⁴th Department of Internal Medicine, Athens, Greece, Athens, Greece, ²⁶Joint Rheumatology Program, University of Athens Medical School, Athens, Greece, ²⁷⁴¹⁷ Army Share Fund Hospital (NIMTS), Department of Rheumatology, Athens, Greece, ZOGRAFOU, Greece, ²⁸Patras University Hospital, University of Patras Medical School, Department of Rheumatology, Patras, Greece, Patras, Akhaia, Greece, ²⁹Patras University Hospital, University of Patras Medical School, Department of Rheumatology, Patras, Greece, Patra, Greece, ³⁰Private practice, Athens, Greece, Athens, Greece, ³¹Private practice, Patras, Greece, Patras, Greece, ³²Private practice, Athens, Greece, Ag. Paraskevi, Greece, ³³First Department of Propedeutic and Internal Medicine, Joint Academic Rheumatology program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ³⁴First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Evros, Greece
Background/Purpose: Axial spondyloarthritis (AxSpA) is a chronic inflammatory disease that significantly impairs quality of life. Although biologic and targeted synthetic DMARDs (b/tsDMARDs) have improved disease…
Abstract Number: 2326 • ACR Convergence 2025
Impact of Regular Exercise, Mobility Impairment, and Obesity on Quality of Life in Patients with Axial Spondyloarthritis: A Cross-Sectional Analysis from the Brazilian Registry of Spondyloarthritis
Rafael Bassara Macedo¹, Maria Eduarda Veiga², Gustavo Resende³, Marcelo Pinheiro⁴, Claudia Marques⁵, Adriana Marinho⁶, Andressa Soares⁷, Cleandro Pires⁸, Débora Rodrigues⁹, Eduarda Souza¹⁰, Glaucio Castro¹¹, Guilherme Bulbol¹², Jamile Carneiro¹³, José Mauro Fernandes¹⁴, Manuella Ochtrop¹⁵, Maria Bernadete Gavi¹⁶, Michel Yazbek¹⁷, Nara Cavalcanti¹⁸, Natalia Machado¹⁹, Olivio Malheiro²⁰, Rejane Vieira²¹, Ricardo Lage²⁰, Rita Menin²², Rywka Golebiovski²³, Sandra Ribeiro¹², Thauana Oliveira²³, Valquiria Diniz¹⁶, Percival Sampaio-Barros²⁴ and Carla Saad², ¹Rheumatology Division, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (USP), Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ³Hospital das Clinicas UFMG, Belo Horizonte, Brazil, ⁴UNIFESP/ EPM, São Paulo, São Paulo, Brazil, ⁵Hospital das Clinicas - Universidade Federal de Pernambuco - UFPE, Recife, Pernambuco, Brazil, ⁶Fundação Hospital do Acre - AC, Rio Branco, Brazil, ⁷Hospital Universitário da Universidade Federal de Santa Catarina (UFSC) - SC, Florianópolis, Brazil, ⁸UNB, Brasilia, Distrito Federal, Brazil, ⁹Fundação Hospital do Acre - AC, Rio Branco, Acre, Brazil, ¹⁰Faculdade de Medicina da Universidade Federal do Amazonas (UFAM) - AM, Manaus, Brazil, ¹¹Hospital Governador Celso Ramos (HCR) - SC, Florianópolis, Santa Catarina, Brazil, ¹²Faculdade de Medicina da Universidade Federal do Amazonas (UFAM) - AM, Manaus, Amazonas, Brazil, ¹³Hospital de Base do Distrito Federal (HBDF) - DF, Brasilia, Distrito Federal, Brazil, ¹⁴Universidade Federal do Maranhão (UFMA) - MA, São Luiz, Maranhao, Brazil, ¹⁵Hospital Universitário Pedro Ernesto / UERJ - RJ, Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁶Universidade Federal do Espírito Santo (UFES) - ES, Vitória, Espirito Santo, Brazil, ¹⁷Universidade Estadual de Campinas (UNICAMP) - SP, Campinhas, Sao Paulo, Brazil, ¹⁸Hospital das Clínicas da Universidade Federal de Pernambuco (UFPE) - PE, Recife, Pernambuco, Brazil, ¹⁹Universidade Fedral do Paraná (UFPR) - PR, Curitiba, Parana, Brazil, ²⁰Hospital das Clínicas da Universidade Federal de Minas Gerais (UFMG) - MG, Belo Horizonte, Minas Gerais, Brazil, ²¹Universidade Estadual do Ceará (UECE) - CE, Fortaleza, Ceara, Brazil, ²²Faculdade de Medicina de São José do Rio Preto (FAMERP) - SP, São José do Rio Preto, Sao Paulo, Brazil, ²³Escola Paulista de Medicina (EPM) - Universidade Federal de São Paulo (UNIFESP) - SP, São Paulo, Sao Paulo, Brazil, ²⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil
Background/Purpose: Axial Spondyloarthritis (axSpA) is a chronic inflammatory disease that impairs quality of life. While pharmacological treatment is central to axSpA management, non-pharmacological strategies are…
Abstract Number: 0250 • ACR Convergence 2025
Autoinflammatory diseases in adult patients. Spanish registry.
Eztizen Labrador-Sanchez¹, Diana Prieto-Peña², Carlota L Iñiguez³, Rafael B. Melero-González⁴, Alberto Ruiz-Roman⁵, Clara Moriano⁶, Paula García-Escudero⁷, Anahy Maria Brandy⁸, Marta López⁹, Fred Anton Pages¹⁰, Maria Camila Osorio-SanJuan¹¹, Nahia Plaza-Aulestia¹², Bryan Josué Flores Robles¹³, Estibaliz Andres Trashaedo¹⁴ and Ricardo Blanco¹⁵, ¹Hospital Universitario San Pedro, Laguardia, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ³Hospital del Bierzo, Ponferrada, Castilla y Leon, Spain, ⁴COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁵Hospital Juan Ramon Jimenez, Huelva, Spain, ⁶Hospital León, LEON, Castilla y Leon, Spain, ⁷Hospital Universitario Álava, Bilbao, Spain, ⁸Hospital Germans Trias i Pujol, Badalona, Spain, ⁹Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, ¹⁰Hospital General de Segovia, Segovia, Spain, ¹¹Hospital Clínico Lozano Blesa, Zaragoza, Spain, ¹²Rheumatology division. Galdakao-Usansolo University Hospital, Galdakao, Spain, ¹³Hospital San Pedro, Logroño, Spain, ¹⁴Hospital San Pedro, Logroño, Spain, ¹⁵Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Autoinflammatory diseases(AIDs) are characterized by recurrent inflammatory episodes resulting from alterations in regulatory genes, activating the innate immune system. Although these diseases primarily occur…
Abstract Number: 0661 • ACR Convergence 2025
Real-world Effectiveness and Usage of Voclosporin: Data from the Enlight-LN Registry
Leanna Wise¹, Laura Geraldino-Pardilla², Niloofar Nobakht³, Mohammad Kamgar³, Amber Rosales⁴, Barbara McIntosh⁴ and Ron Flauto⁴, ¹LAGMC/Keck Medicine of USC, Los Angeles, ²Columbia University, New York, NY, ³University of California Los Angeles, Los Angeles, CA, ⁴Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada
Background/Purpose: The 2024 American College of Rheumatology Lupus Nephritis (LN) Guideline recommends triple immunosuppressive therapy, including the option of a calcineurin inhibitor (CNI)-based regimen, for…
Abstract Number: 1472 • ACR Convergence 2025
Characteristics and Predictors of LLDAS in Survivors of Early Active Lupus: Insights from a Decade-Long Cohort
Amirtha Gopalan¹, keerthi vardhan yerram², Mahesh Gaikwad² and Liza rajasekhar³, ¹Nizams Institute of Medical Sciences, Hyderabad, Hyderabad, Telangana, India, ²Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, ³Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: LLDAS is a desirable state in lupus, with ongoing global reports on its durability and outcomes. The relationship between LLDAS, baseline characteristics, and drug…
Abstract Number: 2342 • ACR Convergence 2025
Real-World Effectiveness and Satisfaction in Biologic-Naïve Patients With Psoriatic Arthritis and Limited Joint Involvement Treated With Risankizumab in the United States and Europe
Andrew Ostor¹, Jessica A. Walsh², Christopher Saffore³, Xiaolan Ye⁴, Manish Patel⁵, Ana Biljan⁶, Jamie Vora⁷, Isabel Truman⁸, Molly Edwards⁸, Gary Milligan⁸ and William Tillett⁹, ¹Australian National University, Canberra, Australia, ²Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ³AbbVie Inc., waukegan, IL, ⁴AbbVie Inc., Mettawa, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., Buffalo Grove, IL, ⁷AbbVie Inc., Palatine, IL, ⁸Adelphi Real World, Bollington, United Kingdom, ⁹Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom
Background/Purpose: This study evaluated real-world effectiveness and patient- and physician-satisfaction with risankizumab (RZB) for biologic-naïve PsA patients with limited joint involvement or oligoarthritis.Methods: Data were…
Abstract Number: 0274 • ACR Convergence 2025
Transplant-free survival in patients with systemic autoimmune rheumatic diseases and progressive pulmonary fibrosis in the ILD-PRO Registry
Sonali Bracken¹, Aparna Swaminathan², Jeremy M Weber³, Megan L Neely⁴, Scott Palmer⁴, Erin Wilfong⁵, Ann Chauffe⁶ and Elizabeth Volkmann⁷, ¹Duke University Medical Center, Durham, NC, USA, Apex, NC, ²Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, USA, Durham, ⁴Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA, Durham, ⁵Vanderbilt University Medical Center, Nashville, TN, USA, Nashville, TN, ⁶Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Newberry, FL, ⁷Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: Progressive pulmonary fibrosis (PPF) is known to be associated with high mortality, but there are few data on the course of PPF in patients…
Abstract Number: 1021 • ACR Convergence 2025
Recent Trends in Cannabis Use Among Individuals with Rheumatic Diseases
Kristin Wipfler¹ and Kaleb Michaud², ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cannabis use has increased substantially in the general population over the past decade, driven by changing legal landscapes and expanding public interest in its…
Abstract Number: 1554 • ACR Convergence 2025
Demographic, Clinical, and Mortality Trends in Scleroderma Patients with Gastric Antral Vascular Ectasia (GAVE): A National Inpatient Analysis
Akanksha Sharma¹, Veera Durga Vaishnavi Kurra² and Neev Mehta³, ¹UPMC Mercy hospital, Pittsburgh, PA, Pittsburgh, PA, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Lahey Hospital and Medical Center, Burlington, MA
Background/Purpose: Gastric antral vascular ectasia (GAVE), commonly known as “watermelon stomach,” is a rare but potentially severe gastrointestinal manifestation in systemic sclerosis (SSc). Despite its…
Abstract Number: 2366 • ACR Convergence 2025
Association Between Skin and Joint Symptom Control and Patient-Reported Pain and Health Status Among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs
Philip J. Mease¹, Nicole Middaugh², Yolanda Muñoz Maldonado², Chao Song³, Skyler Peterson⁴, Robert Low³ and Alexis Ogdie⁵, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³UCB, Smyrna, GA, ⁴CorEvitas, LLC, Waltham, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory condition primarily affecting the joints and skin.1 More severe symptoms are associated with lower health-related quality of…
Abstract Number: 0362 • ACR Convergence 2025
Drug Persistence of IL-17A Inhibitors Among Patients with PsA: Real-World Data from the CorEvitas PsA/SpA Registry
Philip J. Mease¹, Nicole Middaugh², Maya Marchese³, Skyler Peterson³, Burcu Ertugrul Vardar⁴, Russel Burge⁵, Natalia Bello⁶, Marcus Ngantcha⁷, Joseph F Merola⁸, Louis Bessette⁹ and Alexis Ogdie¹⁰, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³CorEvitas, LLC, Waltham, ⁴Eli Lilly Cork GBS Ltd, Dublin, Dublin, Ireland, ⁵Eli Lilly and Company, Indianapolis, ⁶Eli Lilly, Indianapolis, IN, ⁷Eli Lilly GBS Cork Ltd, Cork, Ireland, ⁸Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁹Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ¹⁰University of Pennsylvania, Philadelphia, PA
Background/Purpose: IL-17A inhibitors (IL-17Ai) are considered recommended biologic therapies for PsA per current treatment guidelines1,2. Real-world evidence (RWE) studies on IL-17Ai drug persistence among patients…
Abstract Number: 1064 • ACR Convergence 2025
Characterization of Juvenile Idiopathic Arthritis in Indigenous North American Children enrolled in a North American registry
Hayley M Lynch¹, Jordan E. Roberts¹ and James N. Jarvis², ¹Seattle Children's Hospital/UW, Seattle, WA, ²University of Washington Center for Indigenous Health, Seattle, WA
Background/Purpose: Several studies detail a higher prevalence and severity of juvenile idiopathic arthritis (JIA) in Indigenous North American (INA) children compared to the general population.…
Abstract Number: 1566 • ACR Convergence 2025
Factors Associated with Patient and Physician Global Assessments in Early Systemic Sclerosis
Ellen Romich¹, Alexis Ogdie², Peter Merkel³, Alisa Stephens Shields³, Jessica Alvey⁴, Shervin Assassi⁵, Elana Bernstein⁶, Sonali Bracken⁷, Flavia Castelino⁸, Lorinda Chung⁹, Luke Evnin¹⁰, Tracy Frech¹¹, Jessica Gordon¹², Faye Hant¹³, Monica Harding¹⁴, Laura Hummers¹⁵, Dinesh Khanna¹⁶, Kimberly Lakin¹², Dorota Lebiedz-Odrobina¹⁴, Yiming Luo⁶, Ashima Makol¹⁷, Maureen Mayes¹⁸, Zsuzsanna McMahan¹⁹, Jerry Molitor²⁰, Duncan Moore²¹, Carrie Richardson²², Ami Shah¹⁵, Ankoor Shah²³, Brian Skaug²⁴, Virginia Steen²⁵, John VanBuren¹⁴, Elizabeth Volkmann²⁶, Carleigh Zahn¹⁶ and Nora Sandorfi³, ¹University of Pennsylvania, Media, PA, ²Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ³University of Pennsylvania, Philadelphia, PA, ⁴Utah Data Coordinating Center, University of Utah, Salt Lake City, UT, ⁵Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁶Columbia University, New York, NY, ⁷Duke University Medical Center, Durham, NC, USA, Apex, NC, ⁸Massachusetts General Hospital, Boston, MA, ⁹Stanford University, Stanford, CA, ¹⁰Scleroderma Research Foundation, San Francisco, CA, ¹¹Vanderbilt University Medical Center, Nashville, TN, ¹²Hospital for Special Surgery, New York, NY, ¹³Medical University of South Carolina, Charleston, SC, ¹⁴University of Utah, Salt Lake City, UT, ¹⁵Johns Hopkins Rheumatology, Baltimore, MD, ¹⁶University of Michigan, Ann Arbor, MI, ¹⁷Mayo Clinic, Rochester, MN, ¹⁸UT Health Houston Division of Rheumatology, Houston, TX, ¹⁹UT Health Houston, Houston, TX, ²⁰University of Minnesota, Minneapolis, MN, ²¹Northwestern Memorial Hospital, Chicago, IL, ²²Northwestern University, Chicago, IL, ²³Duke University, Durham, NC, ²⁴UTHealth Houston Division of Rheumatology, Houston, TX, ²⁵Georgetown University School of Medicine, Washington, DC, ²⁶Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: Global assessments by patients and physicians provide unique but complementary perspectives of disease severity. This study aimed to determine the clinical and patient-reported factors…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].